<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Connect Biopharma Holdings Limited — News on 6ix</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited</link>
<description>Latest news and press releases for Connect Biopharma Holdings Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/connect-biopharma-holdings-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7441d51cc36e475331fd3.webp</url>
<title>Connect Biopharma Holdings Limited</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited</link>
</image>
<item>
<title>Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-announces-enrollment-in-phase-2-seabreeze-stat-studies-will-continue-as-planned-following-pre-specified-interim-analysis</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-announces-enrollment-in-phase-2-seabreeze-stat-studies-will-continue-as-planned-following-pre-specified-interim-analysis</guid>
<pubDate>Thu, 23 Apr 2026 04:00:00 GMT</pubDate>
<description>Expect to report topline data from both studies mid-2026 SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB)</description>
</item>
<item>
<title>Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-reports-2025-full-year-financial-results-and-provides-business-update-3</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-reports-2025-full-year-financial-results-and-provides-business-update-3</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in</description>
</item>
<item>
<title>Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-announces-positive-topline-data-from-its-phase-1-study-of-intravenous-iv-rademikibart-in-patients-with-asthma-or-copd</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-announces-positive-topline-data-from-its-phase-1-study-of-intravenous-iv-rademikibart-in-patients-with-asthma-or-copd</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement</description>
</item>
<item>
<title>Connect Biopharma Announces $20.2 Million Private Placement Financing</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-announces-dollar202-million-private-placement-financing</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-announces-dollar202-million-private-placement-financing</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect</description>
</item>
<item>
<title>Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/results-from-phase-3-study-of-rademikibart-in-moderate-to-severe-atopic-dermatitis-to-be-presented-in-the-late-breaking-research-session-at-the-2026-american-academy-of-dermatology-aad-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/results-from-phase-3-study-of-rademikibart-in-moderate-to-severe-atopic-dermatitis-to-be-presented-in-the-late-breaking-research-session-at-the-2026-american-academy-of-dermatology-aad-annual-meeting</guid>
<pubDate>Tue, 10 Mar 2026 13:00:00 GMT</pubDate>
<description>SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the results of a Phase 3 study of rademikibart in moderate-to-severe atopic dermatitis (AD) conducted by the Company’s partner in China, Simcere Pharmaceutical Co., Ltd. (Simcere), will be presented in the Late-Breaking R</description>
</item>
<item>
<title>Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-to-present-at-the-leerink-partners-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-to-present-at-the-leerink-partners-global-healthcare-conference</guid>
<pubDate>Tue, 03 Mar 2026 14:00:00 GMT</pubDate>
<description>SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026 at 8:00 a.m. ET. The live webcast of the presentation may be accessed via the In</description>
</item>
<item>
<title>Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Thu, 19 Feb 2026 14:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26th, 2026 at 2:40 p.m. ET. The live webcast of the presentation may be accessed via the Invest</description>
</item>
<item>
<title>Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-highlights-new-mechanism-of-action-data-for-rademikibart-and-outlines-priorities-for-2026</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-highlights-new-mechanism-of-action-data-for-rademikibart-and-outlines-priorities-for-2026</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart – – Recruitment ongoing for Phase 1b</description>
</item>
<item>
<title>Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-to-present-at-the-8th-annual-evercore-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-to-present-at-the-8th-annual-evercore-healthcare-conference</guid>
<pubDate>Mon, 24 Nov 2025 14:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd, 2025 at 10:50 a.m. ET. The live webcast of the presentation may be accessed via the In</description>
</item>
<item>
<title>Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-and-bimergen-energy-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-and-bimergen-energy-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv</guid>
<pubDate>Fri, 14 Nov 2025 14:00:00 GMT</pubDate>
<description>ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies will air interviews with Connect Biopharma Holdings Limited (Nasdaq:CNTB) and Bimergen Energy Corp. (OCTQB:BESS) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...</description>
</item>
<item>
<title>Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-reports-third-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-reports-third-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>– Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 –</description>
</item>
<item>
<title>Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/join-connect-biopharmas-exclusive-live-investor-webinar-and-qanda-session-on-november-3</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/join-connect-biopharmas-exclusive-live-investor-webinar-and-qanda-session-on-november-3</guid>
<pubDate>Thu, 30 Oct 2025 12:30:00 GMT</pubDate>
<description>ORLANDO, FLORIDA / ACCESS Newswire / October 30, 2025 / RedChip Companies will host an investor webinar with Connect Biopharma Holdings Limited (Nasdaq:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused ...</description>
</item>
<item>
<title>Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-presents-data-supporting-rademikibart-at-the-european-respiratory-society-congress-2025</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-presents-data-supporting-rademikibart-at-the-european-respiratory-society-congress-2025</guid>
<pubDate>Mon, 29 Sep 2025 13:00:00 GMT</pubDate>
<description>– Rademikibart demonstrated rapid and significant improvement in lung function and asthma control in patients, with greatest improvements observed in those with elevated baseline levels of key type 2 inflammatory markers – – Significant reduction in annualized exacerbations observed in patients with one or more elevated type 2 inflammatory markers at baseline – – Data supports ongoing Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from bo</description>
</item>
<item>
<title>Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-announces-two-presentations-at-the-european-respiratory-society-ers-congress-2025</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-announces-two-presentations-at-the-european-respiratory-society-ers-congress-2025</guid>
<pubDate>Thu, 04 Sep 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage</description>
</item>
<item>
<title>Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-completes-termination-of-its-american-depositary-receipt-program-and-directly-lists-its-ordinary-shares-on-nasdaq</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-completes-termination-of-its-american-depositary-receipt-program-and-directly-lists-its-ordinary-shares-on-nasdaq</guid>
<pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage</description>
</item>
<item>
<title>Connect Biopharma to Present at Two Upcoming Investor Conferences in September</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-to-present-at-two-upcoming-investor-conferences-in-september</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-to-present-at-two-upcoming-investor-conferences-in-september</guid>
<pubDate>Wed, 27 Aug 2025 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in the following upcoming conferences: Cantor Global Healthcare Conference 2025Format: Fireside ChatDate: Wednesday, September 3rd, 2025Time: 3:20 p.m. ETWebcast Link: Register Here H.C.</description>
</item>
<item>
<title>Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-teams-with-ickey-woods-and-the-jovante-woods-foundation-to-expand-asthma-education-program-nationwide</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-teams-with-ickey-woods-and-the-jovante-woods-foundation-to-expand-asthma-education-program-nationwide</guid>
<pubDate>Thu, 14 Aug 2025 12:00:00 GMT</pubDate>
<description>Ickey & Jovante Woods Ickey Woods with his son Jovante. Company and Former Cincinnati Bengals Running Back Known for the “Ickey Shuffle” Collaborate to Raise Awareness and Drive Asthma Education with Focus on Acute Attacks SAN DIEGO and CINCINNATI, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company) and the Jovante Woods Foundation (the Foundation) today kicked off a collaboration to expand the Foundation’s asthma educa</description>
</item>
<item>
<title>Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-reports-second-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-reports-second-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Wed, 13 Aug 2025 04:00:00 GMT</pubDate>
<description>– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations – – Presented positive data</description>
</item>
<item>
<title>Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-appoints-industry-veteran-jim-schoeneck-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-appoints-industry-veteran-jim-schoeneck-to-its-board-of-directors</guid>
<pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
<description>– Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding</description>
</item>
<item>
<title>Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq</title>
<link>https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-announces-plans-to-terminate-its-american-depositary-receipt-program-and-directly-list-its-ordinary-shares-on-nasdaq</link>
<guid isPermaLink="true">https://6ix.com/company/connect-biopharma-holdings-limited/news/connect-biopharma-announces-plans-to-terminate-its-american-depositary-receipt-program-and-directly-list-its-ordinary-shares-on-nasdaq</guid>
<pubDate>Mon, 21 Jul 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage</description>
</item>
</channel>
</rss>